Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS
Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers
Cancer (2012) 118:2021-2030.
BACKGROUND: Although breast cancer screening with mammography and magnetic resonance imaging (MRI) is recommended for breast cancer-susceptibility gene (BRCA) mutation carriers, there is no current consensus on the optimal screening regimen. METHODS: The authors used a computer simulation model to compare 6 annual screening strategies (film mammography [FM], digital mammography [DM], FM and magnetic resonance imaging [MRI] or DM and MRI contemporaneously, and alternating FM/ MRI or DM/ MRI at 6-month intervals) beginning at ages 25 years, 30 years, 35 years, and 40 years, and 2 strategies of annual MRI with delayed alternating DM/ FM versus clinical surveillance alone. Strategies were evaluated without and with mammography-induced breast cancer risk using 2 models of excess relative risk. Input parameters were obtained from the medical literature, publicly available databases, and calibration. RESULTS: Without radiation risk effects, alternating DM/ MRI starting at age 25 years provided the highest life expectancy (BRCA1, 72.52 years, BRCA2, 77.63 years). When radiation risk was included, a small proportion of diagnosed cancers was attributable to radiation exposure (BRCA1, < 2%; BRCA2, < 4%). With radiation risk, alternating DM/ MRI at age 25 years or annual MRI at age 25 years/ delayed alternating DM at age 30 years was the most effective, depending on the radiation risk model used. Alternating DM/ MRI starting at age 25 years also produced the highest number of false-positive screens per woman (BRCA1, 4.5 BRCA2, 8.1). CONCLUSIONS: Annual MRI at age 25 years/ delayed alternating DM at age 30 years is probably the most effective screening strategy in BRCA mutation carriers. Screening benefits, associated risks, and personal acceptance of false-positive results should be considered in choosing the optimal screening strategy for individual women. Cancer 2012; 118: 2021-30. VC 2011 American Cancer Society.
Publication Date: 2012-04-01.
PMCID: PMC3245774
Last updated on Thursday, April 02, 2020